End of Day, Cause and Effect Read more…
The 6 W’s: Who, what, where, when, why and what of it … Read more…
Benefits of MultiStem therapy for treating stroke using standard preclinical models Read more…
P2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer (MBC). Read more…
Good morning! Here’s what you … might need to know to start the day. Read more…
End of Day, Cause and Effect Read more…
The 6 W’s: Who, what, where, when, why and what of it … Read more…
STEM initiates a P1/2 clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD). Read more…
Good morning! Here’s what you … might need to know to start the day. Read more…
End of Day, Cause and Effect Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.